Experimental investigation in LIFUS5/Mod2 facility of spiral-tube steam Generator Rupture scenarios for ELFR

In the framework of the European Commission LEADER project, an experimental campaign of seven tests was performed in the LIFUS5/Mod2 facility, at ENEA CR Brasimone, for investigating the postulated Steam Generator Tube Rupture (SGTR) event in a relevant configuration for the Spiral-Tube Steam Generator (STSG) of the European Lead Fast Reactor (ELFR). The LIFUS5/Mod2 facility is composed by a water tank of 15 L injecting subcooled water up to 200 bar into the reaction tank of 100 L (420 mm of diameter), which is connected by a 3 inch pipe to the dump tank of 2 m3. A dedicated test section was designed, assembled and implemented in the reaction tank. It is composed by 188 tubes, vertically disposed with triangular pitch inside a cylindrical support. This tube bundle is representative of a portion of the STSG of ELFR. The cylindrical support is closed at the lower and upper end by two tube plates and has a perforated lateral shell (300 mm of diameter and 400 mm high). The reaction tank is filled by Lead- Bismuth Eutectic alloy (LBE) at 400°C up to the top tube plate, with an argon cover gas at about 2 bar. The water is injected at about 180 bar and 270°C through the central tube, at middle height of the bundle. The water-LBE interaction is characterised by high quality data acquisition system: 6 fast Pressure Transducers (PTs) working at 10 kHz for precisely characterize the first narrow injection peaks, 70 low constant time Thermocouples (TCs) to understand the vapour evolution path and 13 strain gages (SGGs) for measuring the strain of the bundle and main vessel. The overall LEADER experimental campaign is constituted by seven tests, divided in three series (B1, B2 and B3), characterized by different injection orifice diameters of 4, 8.9 and 12.6 mm, respectively. This paper presents the experimental results of the first two tests of series B2 (B2.1 and B2.2) having 8.9 mm of injection orifice. The first test analysed showed a first narrow pressure peak of about 32 bar, some milliseconds after the cap rupture instant. The following pressurization due to the evaporation of water entered into the reaction vessel was of an analogues magnitude for both the tests (about 50 bar) and lasted some tenths of second. The water/LBE interaction lower temperature was reached on the inner ranks of tubes, about 150°C. The outer rank was cooled down to about 300°C. The strain gage measurements showed a decreasing deformation on the tubes toward the outer positions. No ruptures were observed on tubes surrounding the injector. The amount of LBE transported into the dump tank was strongly dependent on the LBE level in the reaction tank at the start of the tests and about 200 kg

A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive

In this study we tested the effectiveness of the combined administration of cyproterone acetate (CPA) and testosterone enanthate (TE) in suppressing spermatogenesis. After a control phase of 3 months, 15 normal men were randomized to receive TE (100 mg/week) plus CPA at a dose of 100 mg/day (CPA-100; n = 5) or 50 mg/day (CPA-50; n = 5) or TE (100 mg/week) alone (n = 5) for 16 weeks. Semen analysis was performed every 2 weeks. Every 4 weeks, fasting blood samples were drawn for the measurement of LH, FSH, testosterone, estradiol, and biochemical and hematological parameters; subjects underwent a physical examination; and they and their partners filled in a sexual and behavioral questionnaire. Regardless of the dose, each of the 10 subjects receiving CPA plus TE became azoospermic, whereas only 3 of 5 subjects treated with TE alone achieved azoospermia. Times to azoospermia were 6.8 +/- 0.5, 8.4 +/- 1.0, and 14.0 +/- 1.2 weeks in groups CPA-100, CPA-50, and TE alone, respectively (P = NS). Throughout treatment, both gonadotropins tended to be higher in the TE alone group than in the other groups. This difference was mostly due to the higher gonadotropin levels present in the 2 men treated with TE alone that remained oligospermic. No difference in testosterone or estradiol levels was found among the groups. No significant change in lipoprotein levels or liver function tests could be detected. In the CPA-100 and CPA-50 groups, hemoglobin, hematocrit, and red blood cells were lower at the end of the treatment phase, whereas no change was detected in TE alone group. A tendency for a decrease in body weight was detected in subjects treated with CPA, whereas there was no change in subjects receiving TE alone. At the end of the treatment phase, a decrease in testis size was present in all groups. There was no significant change in sexual function, aggressive behavior, mood states, or satisfaction with relationship in any group. These results suggest that the combined administration of CPA and TE is very effective in suppressing spermatogenesis and may represent a promising regimen for reversible contraception in males